Immuneering (IMRX)
(Delayed Data from NSDQ)
$3.21 USD
+0.79 (32.64%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.22 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Immuneering Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -53.47 | -50.51 | -33.54 | -17.04 | NA |
Depreciation/Amortization & Depletion | -0.25 | 0.63 | 0.29 | 0.08 | NA |
Net Change from Assets/Liabilities | -0.97 | 1.72 | 0.90 | 1.25 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 5.73 | 4.07 | 1.50 | 1.09 | NA |
Net Cash From Operating Activities | -48.97 | -44.10 | -30.85 | -14.62 | NA |
Property & Equipment | -0.34 | -0.74 | -0.06 | -0.05 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 7.64 | 42.57 | -75.63 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.07 | 0.00 | NA |
Net Cash from Investing Activities | 7.30 | 41.83 | -75.62 | -0.05 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 28.64 | 0.30 | 146.39 | 37.98 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.20 | -0.28 | -2.12 | 0.00 | NA |
Net Cash from Financing Activities | 28.44 | 0.02 | 144.26 | 37.98 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -13.23 | -2.25 | 37.80 | 23.31 | NA |
Cash at Beginning of Period | 72.64 | 74.89 | 37.09 | 13.78 | NA |
Cash at End of Period | 59.41 | 72.64 | 74.89 | 37.09 | NA |
Diluted Net EPS | -1.88 | -1.91 | -2.46 | NA | NA |
Fiscal Year End for Immuneering Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -28.39 | -14.31 | -53.47 | -38.39 | -25.79 |
Depreciation/Amortization & Depletion | 0.19 | 0.03 | -0.25 | -0.04 | 0.08 |
Net Change from Assets/Liabilities | -1.96 | -2.68 | -0.97 | -2.86 | -2.06 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.14 | 1.47 | 5.73 | 4.09 | 2.61 |
Net Cash From Operating Activities | -27.02 | -15.49 | -48.97 | -37.19 | -25.17 |
Property & Equipment | -0.07 | -0.04 | -0.34 | -0.17 | -0.11 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 26.43 | 21.43 | 7.64 | 4.34 | 28.25 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 26.36 | 21.39 | 7.30 | 4.16 | 28.14 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.98 | 0.98 | 28.64 | 28.64 | 28.62 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.20 | -0.20 | -0.20 |
Net Cash from Financing Activities | 0.98 | 0.98 | 28.44 | 28.43 | 28.41 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 0.32 | 6.88 | -13.23 | -4.60 | 31.38 |
Cash at Beginning of Period | 59.41 | 59.41 | 72.64 | 72.64 | 72.64 |
Cash at End of Period | 59.73 | 66.29 | 59.41 | 68.04 | 104.02 |
Diluted Net EPS | -0.47 | -0.49 | -0.51 | -0.43 | -0.43 |